Susan

Introduction of Diagnostic and Supplemental Imaging Legislation Could Benefit Thousands of Virginians

Retrieved on: 
Thursday, January 19, 2023
Disease, Prognosis, Face, COVID-19, Death, Susan, Breast MRI, Health, Google Images, Breast, Woman, Legislation, Diagnosis, Patient, Biopsy, Cancer, McQuinn, MRI, Heart, Breast cancer, Medical imaging, Policy

RICHMOND, Va., Jan. 19, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, applauds Delegate Shelly Simonds (D-Hampton Roads) and Delores McQuinn (D-Richmond) for working with Komen to introduce legislation that would remove financial barriers to imaging that can rule out breast cancer or confirm the need for a biopsy. In 2023, more than 7,810 people will be diagnosed with breast cancer and more than 1,150 will die of the disease.

Key Points: 
  • "This legislation can make an immediate impact for thousands of people who require diagnostic or supplemental breast imaging yet are unable to afford it and often forego the tests," said Molly Guthrie, Vice President of Policy and Advocacy at Susan G. Komen.
  • HB 1815 , introduced by Delegate Simonds, would eliminate out-of-pocket costs for diagnostic and supplemental breast imaging (such as an MRI, ultrasound, diagnostic mammogram) when medically necessary.
  • An estimated 16 percent of people who receive annual screening mammograms nationwide get called back for diagnostic imaging.
  • More diagnostic and supplemental breast imaging is likely going to be needed due to "missed" breast cancers during the COVID-19 pandemic.

Introduction of Diagnostic and Supplemental Imaging Legislation Could Benefit Thousands of Washingtonians

Retrieved on: 
Wednesday, January 18, 2023
Disease, COVID-19, Sean D. Kirkland, Death, Family, Susan, Breast MRI, Google Images, Breast, Woman, Legislation, Patient, Biopsy, MRI, Breast cancer, Medical imaging, Birth control, Policy

OLYMPIA, Wash., Jan. 18, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, applauds Senator Lynda Wilson (R-Vancouver) and Representative Amy Walen (D-Kirkland) for working with Komen to introduce legislation that would remove financial barriers to imaging that can rule out breast cancer or confirm the need for a biopsy. In 2023, more than 7,050 people will be diagnosed with breast cancer and more than 960 will die of the disease.

Key Points: 
  • "This legislation can make an immediate impact for thousands of people who require diagnostic or supplemental breast imaging yet are unable to afford it and often forego the tests," said Molly Guthrie, Vice President of Policy and Advocacy at Susan G. Komen.
  • SB 5396 and HB 1261 , introduced by Sen. Wilson and Rep. Walen, would eliminate out-of-pocket costs for diagnostic and supplemental breast imaging (such as an MRI, ultrasound, diagnostic mammogram) when medically necessary.
  • An estimated 16 percent of people who receive annual screening mammograms nationwide get called back for diagnostic imaging.
  • More diagnostic and supplemental breast imaging is likely going to be needed due to "missed" breast cancers during the COVID-19 pandemic.

Susan G. Komen® Launches Restorative Fitness Program for the Breast Cancer Community Led by YogaWorks Instructors

Retrieved on: 
Tuesday, January 17, 2023
Breast cancer, Human, Partnership, Patient, Susan, Survivor, Quality of life, Yoga, Collection, YogaWorks, Research, Birth control, Medical imaging

LOS ANGELES, Jan. 17, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, today announced a first-of-its kind partnership with YogaWorks to provide online classes geared to the breast cancer community. Patients, survivors, and the breast cancer community will be given access to a restorative fitness program that will support their breast cancer journey at absolutely no cost.

Key Points: 
  • LOS ANGELES, Jan. 17, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, today announced a first-of-its kind partnership with YogaWorks to provide online classes geared to the breast cancer community.
  • Patients, survivors, and the breast cancer community will be given access to a restorative fitness program that will support their breast cancer journey at absolutely no cost.
  • Research shows that yoga is an effective therapy to help patients and survivors manage the side effects of breast cancer and breast cancer treatment to improve their overall quality of life.
  • Komen is delighted to support the efforts of YogaWorks to provide a unique fitness regimen that has the breast cancer community in mind.

Mahoko Hara, Executive Chair of Aviation Capital Group, Honored with the 2023 AWAR Trailblazer Award

Retrieved on: 
Tuesday, January 17, 2023
Professional Services, Air, Transport, Aerospace, Manufacturing, Finance, Dai, Pacific Life, Shinsei Bank, TC, DE, Executive, Cure, Susan, Mentorship, Strategic planning, Capital Group Companies, Organization, Conference, Woman, NAACP Theatre Award – Trailblazer Award, ISTAT, Dai-Ichi Kangyo Bank, Mizuho Bank, Senior management, ESG, Acquisition, ACG, Multimedia, Female, Citibank, Management, Aviation

Aviation Capital Group LLC (“ACG”) is delighted to announce that its Executive Chair, Mahoko Hara, has received the 2023 Trailblazer Award from Advancing Women in Aviation Roundtable (“AWAR”).

Key Points: 
  • Aviation Capital Group LLC (“ACG”) is delighted to announce that its Executive Chair, Mahoko Hara, has received the 2023 Trailblazer Award from Advancing Women in Aviation Roundtable (“AWAR”).
  • View the full release here: https://www.businesswire.com/news/home/20230117005731/en/
    Mahoko Hara, Executive Chair of Aviation Capital Group, Honored with the 2023 AWAR Trailblazer Award (Photo: Business Wire)
    AWAR is a non-profit corporation on a mission to engage with CEOs and other senior executives to build awareness and develop actionable strategies to promote the development and advancement of women leaders in the aviation industry.
  • “We are delighted to present Mahoko Hara with the 2023 AWAR Trailblazer Award,” said Emily Wicker, president of AWAR.
  • The Trailblazer Award was presented at the AWAR Annual Leaders luncheon in Dublin, Ireland.

Introduction of Diagnostic and Supplemental Imaging Legislation Could Benefit Thousands of New Mexicans

Retrieved on: 
Wednesday, January 11, 2023
Disease, COVID-19, Death, Susan, Risk, Breast MRI, Google Images, New Mexican, Breast, Legislation, Patient, Biopsy, MRI, Breast cancer, HB, Komen, Medical imaging, Policy

SANTA FE, N.M., Jan. 11, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, applauds Representative Christine Chandler (D-Los Alamos) for working with Komen to introduce legislation that would remove financial barriers to imaging that can rule out breast cancer or confirm the need for a biopsy. Last year alone, more than 1,700 individuals were diagnosed with breast cancer and more than 290 died of the disease in New Mexico.

Key Points: 
  • "This legislation can make an immediate impact for thousands of people who require diagnostic or supplemental breast imaging, yet are unable to afford it and often forego the tests," said Molly Guthrie, Vice President of Policy and Advocacy at Susan G. Komen.
  • HB 27 , introduced by Rep. Chandler, would eliminate out-of-pocket costs for diagnostic and supplemental breast imaging (such as an MRI, ultrasound, diagnostic mammogram) when medically necessary.
  • An estimated 16 percent of people who receive annual screening mammograms nationwide get called back for diagnostic imaging.
  • More diagnostic and supplemental breast imaging is likely going to be needed due to "missed" breast cancers during the COVID-19 pandemic.

iCAD Announces Board of Directors Transition

Retrieved on: 
Wednesday, January 11, 2023
ICAD, Digital, Texas Instruments, Susan, Senior, Organization, Google Health, Growth, CMO, United Way Worldwide, Mammography, Breast cancer, Management

NASHUA, N.H., Jan. 11, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Dana Brown as Executive Chair of the Board of Directors.

Key Points: 
  • NASHUA, N.H., Jan. 11, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Dana Brown as Executive Chair of the Board of Directors.
  • Ms. Brown has been a non-executive board member since February 2022.
  • Prior to joining iCAD’s board, Ms. Brown was the Senior Vice President, Chief Strategy and Operations Officer for Susan G. Komen®, the world’s leading nonprofit breast cancer advocacy organization.
  • “I would also like to thank Timothy Irish for his significant contribution to the Company as Chairman of the Board of Directors over the past year, as he has worked closely with me to close some of the most meaningful partnerships in the company’s history.

Introduction of Diagnostic and Supplemental Imaging Legislation Could Benefit Thousands of Missourians

Retrieved on: 
Tuesday, January 10, 2023
Google Images, Legislation, MRI, Head, COVID-19, Death, Breast, Breast MRI, Breast cancer, Disease, Patient, Insurance, Susan, HB, Diagnosis, Woman, Biopsy, Medical imaging, The Missourians, Policy

ST. LOUIS, Jan. 10, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, applauds Representative Brenda Shields (R-St. Joseph) for working with Komen to introduce legislation that would remove financial barriers to imaging that can rule out breast cancer or confirm the need for a biopsy. Last year alone, more than 5,560 individuals were diagnosed with breast cancer and more than 820 died of the disease in Missouri.

Key Points: 
  • "This legislation can make an immediate impact for thousands of people who require diagnostic or supplemental breast imaging yet are unable to afford it and often forego the tests," said Molly Guthrie, Vice President of Policy and Advocacy at Susan G. Komen.
  • HB 575 , introduced by Rep. Shields, would eliminate out-of-pocket costs for diagnostic and supplemental breast imaging (such as an MRI, ultrasound, diagnostic mammogram) when medically necessary.
  • An estimated 16 percent of people who receive annual screening mammograms nationwide get called back for diagnostic imaging.
  • More diagnostic and supplemental breast imaging is likely going to be needed due to "missed" breast cancers during the COVID-19 pandemic.

Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy

Retrieved on: 
Wednesday, December 21, 2022
Science, Biotechnology, Research, Oncology, Health, Health Technology, Clinical Trials, Other Health, Partnership, Blood, Research, Knowledge, DNA, Health, Risk, Neoplasm, Breast cancer, Helmy Eltoukhy, Patient, MRD, Mission, Susan, Recurrence, SVP, GH, Medical imaging, Science

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Susan G. Komen®, the world’s leading breast cancer organization, announced today that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify early-stage breast cancer patients who are at high risk of disease recurrence and may benefit from additional monitoring or therapy.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Susan G. Komen®, the world’s leading breast cancer organization, announced today that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify early-stage breast cancer patients who are at high risk of disease recurrence and may benefit from additional monitoring or therapy.
  • The focus of the partnership will be to support the development of clinical utility data for Guardant Reveal™, a blood test for the detection of minimal residual disease (MRD) in patients with early-stage breast cancer.
  • The test detects circulating tumor DNA (ctDNA) in the blood as a measurement of MRD, the presence of which indicates a high risk for disease recurrence.
  • A critical element of the partnership is the use of input from patient advocates to guide the research study design.

Bioethics International Publishes New Index to Score Pharma Companies on Clinical Trial Diversity in BMJ Medicine

Retrieved on: 
Thursday, January 5, 2023
Benchmark, Race (human categorization), Eli Lilly and Company, Clinical trial, Stanford University School of Medicine, Ecosystem, Ethics, Stanford Law School, Associate, Bioethics, Food, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sanofi, Research, Takeda Pharmaceutical Company, Merck, United Therapeutics, Female, Health policy, Male, Puma, Breast cancer, Stanford University, Social justice, Equity, Patient, Yale School of Medicine, Gold, Policy, Bristol Myers Squibb, Physician, Safety, Eye, FDA, Susan, Puma Biotechnology, Pharmaceutical industry, Yale University, Woman, Inclusivism, Medicine

Bioethics International is a not-for-profit organization dedicated to raising the bar on ethics, equity, trustworthiness, and patient-centricity in the biopharmaceutical industry.

Key Points: 
  • Bioethics International is a not-for-profit organization dedicated to raising the bar on ethics, equity, trustworthiness, and patient-centricity in the biopharmaceutical industry.
  • – received the gold rating, scoring in the top quartile on clinical trial diversity performance.
  • "The purpose of the fair inclusion score is to provide companies and industry partners with a metric to assess how well companies are doing improving clinical trial diversity.
  • The fair inclusion score provides a tool to assess the diversity of clinical research and track progress over time.

Bosley Gives Back in the Fight Against Breast Cancer

Retrieved on: 
Thursday, December 22, 2022
Organization, Breast cancer, Patient, Susan, Disease, Hair loss, Diagnosis, Risk, Health, Science, Research, Breast cancer awareness, Cancer, Woman, Dentistry, Birth control, Bosley

While breast cancer research and advocacy is just one of the causes we choose to focus on, it's one that's close to our hearts.

Key Points: 
  • While breast cancer research and advocacy is just one of the causes we choose to focus on, it's one that's close to our hearts.
  • Bosley has over 450 employees, and sadly most of us do know someone or know of someone who has been affected by breast cancer.
  • Every October, Bosley donates a portion of all revenue to a Breast Cancer Awareness organization – but our team members are involved on a more individual basis, too.
  • "When you support Komen, you support the only breast cancer organization taking a comprehensive, 360-degree approach to fight breast cancer across all fronts, supporting millions of people in the U.S. and worldwide," said Paula Schneider, president and CEO of Susan G. Komen.